SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 81.47 |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 57.81 |
| Book Value / Share | 3.80 |
| Price / Book | n/a |
| NCAV ($M) | 44.84 |
| NCAV / Share | 2.94 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.37 |
| Return on Assets (ROA) | -0.63 |
| Return on Equity (ROE) | -0.85 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.23 |
| Current Ratio | 3.25 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 84.19 |
| Assets | 97.16 |
| Liabilities | 39.35 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 12.97 |
| Operating Income | -106.66 |
| Net Income | -105.94 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -110.27 |
| Cash from Investing | -36.06 |
| Cash from Financing | -6.22 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Ridgeback Capital Investments L.P. | 9.90 | 15.34 | |
| 13G/A | 683 Capital Management, LLC | 4.80 | -21.96 | |
| 13G/A | BlackRock Inc. | 0.80 | -84.96 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 15,918 | 63,063 | 25.24 | |
| 5,616 | 5,161 | 108.82 | |
| 17,061 | 18,220 | 93.64 | |
| 9,052 | 9,242 | 97.94 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ADTX – Aditxt, Inc. | ADVM – Adverum Biotechnologies, Inc. |
| AEZS – Aeterna Zentaris Inc. | AGEN – Agenus Inc. |
| AIMD – Ainos, Inc. |